APOE and Alzheimer disease: In cognitively unimpaired individuals, a biomarker combination of plasma p-tau181 and p-tau217 along with the APOE genotype is not significantly better at predicting conversion to AD (AUC = 0.88 [0.82–0.95]) compared to p-tau181 alone (AUC = 0.84 [0.77–0.92]) [170].